Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Jane Williams
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.
Without challenge, there is no change – the move to precision medicine
Posted 5th September 2018 by Jane Williams
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.
Pricing Pressure, Payer Perspectives and Innovative Diagnostic Platforms
Posted 24th August 2018 by Jane Williams
We spoke to Alex Bastian about how he got started in precision medicine, where he sees it going and how he intends to use real world evidence to unlock the potential around personalised approaches to drug development:
What’s been happening in precision medicine this month?
Posted 30th July 2018 by Jane Williams
There has been some interesting news, discoveries and development to catch up on this month in the world of precision medicine. Take a look at the list below to find out more:
Connecting Cancer Biology to Clinical Oncology: Still a World to Win
Posted 14th May 2018 by Jane Williams
Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.
The Challenges & Considerations of Reporting Somatic Variants in Cancer
Posted 30th April 2018 by Jane Williams
Industrial and “omic” scale mutational profiling of solid tumours are possible as a result of massively parallel sequencing technology. However, these clinical genomic testing capabilities have also brought myriad new biological, technical and operational challenges not encountered in monogenic disorder testing. All of this impacts the interpretation and reporting of somatic variants. As a testament to the nascency of this field, the first published consensus guidelines for interpretation of variants in cancer was only released in early 2017.
Large-Scale Genetics Research: Q&A with Aris Baras
Posted 20th April 2018 by Jane Williams
With genetic data making headlines, Aris Baras reflects on how genetic research can further advancements in medicine and delves into how his team’s work on large-scale approach is paving the way for new discoveries and enhanced patient care.
Immunotherapy for Malignant Mesothelioma
Posted 23rd March 2018 by Jane Williams
The current field of cancer research is seeing gains in almost every aspect of care, from the foundations of the disease to the development of successful treatment. With increased funding and attention to oncology care, immunotherapy and precision medicine are among the most promising patient-centred areas of current research and translational medicine.